There are 2789 resources available
1150TiP - A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Presenter: Kim Margolin
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1030TiP - An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Wallace Akerley
Session: ePoster Display
Resources:
Abstract
1031TiP - Vascular intervention combined with camrelizumab and apatinib for patients with inoperable solid tumors: An exploratory study
Presenter: Feng Gao
Session: ePoster Display
1033TiP - A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Presenter: Kyriakos Papadopoulos
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1212P - Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
Presenter: James Yang Yang
Session: ePoster Display